Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

ImmunityBio (IBRX) EBT Margin (2016 - 2025)

ImmunityBio (IBRX) has disclosed EBT Margin for 12 consecutive years, with 162.19% as the latest value for Q4 2025.

  • On a quarterly basis, EBT Margin rose 62143.0% to 162.19% in Q4 2025 year-over-year; TTM through Dec 2025 was 310.37%, a 249496.0% increase, with the full-year FY2025 number at 310.37%, up 249496.0% from a year prior.
  • EBT Margin was 162.19% for Q4 2025 at ImmunityBio, up from 209.94% in the prior quarter.
  • In the past five years, EBT Margin ranged from a high of 162.19% in Q4 2025 to a low of 735700.0% in Q1 2022.
  • A 5-year average of 124844.02% and a median of 45139.93% in 2023 define the central range for EBT Margin.
  • Peak YoY movement for EBT Margin: surged 198243333bps in 2021, then plummeted -67780432bps in 2022.
  • ImmunityBio's EBT Margin stood at 23474.87% in 2021, then plummeted by -532bps to 148345.21% in 2022, then decreased by -13bps to 167952.52% in 2023, then skyrocketed by 100bps to 783.62% in 2024, then skyrocketed by 79bps to 162.19% in 2025.
  • Per Business Quant, the three most recent readings for IBRX's EBT Margin are 162.19% (Q4 2025), 209.94% (Q3 2025), and 349.31% (Q2 2025).